US FDA approves Novo's insulin injection for type 2 diabetes

March 26 (Reuters) - The U.S. Food and Drug Administration has approved Novo Nordisk's NOVOb.CO insulin injection, Awiqli, to control blood sugar levels in adults living with type 2 diabetes, the company said on Thursday.

• Novo Nordisk expects to launch the insulin product in the United States in the second half of 2026.

• The Danish drugmaker said its product is the "first-ever" once-weekly basal insulin approved by the FDA.

• A once‑weekly option reduces injections from seven to one, which is a major quality‑of‑life improvement for people with type 2 diabetes.

• Awiqli is approved in the European Union and 13 more countries, the company said.